Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 4/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915454 | 1.00 | KMT2A (0.41) | KMT2AMEN1NPC1RAB9AOXTR | |
| SCHEMBL3662388 | 0.84 | HTR2C (0.40) | KMT2AMEN1NPC1OXTRALDH1A1 | |
| SCHEMBL226527 | 0.84 | HTR2C (0.40) | KMT2AMEN1NPC1OXTRALDH1A1 | |
| SCHEMBL226255 | 0.84 | HTR2C (0.40) | KMT2AMEN1NPC1OXTRALDH1A1 | |
| SCHEMBL7494216 | 0.82 | ALDH1A1 (0.40) | KMT2AOXTRAVPR1AALDH1A1LMNA | |
| SCHEMBL22733859 | 0.81 | CTSD (0.35) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL12184848 | 0.80 | LMNA (0.41) | KMT2AMEN1OXTRALDH1A1LMNA | |
| SCHEMBL24854873 | 0.79 | ADRB2 (0.36) | — | |
| SCHEMBL27308751 | 0.79 | MEN1 (0.36) | KMT2AMEN1OXTRAVPR1AALDH1A1 | |
| SCHEMBL14640493 | 0.79 | POLB (0.53) | KMT2AMEN1NPC1RAB9AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | REN, ACE, AGTR1 | KMT2A 2465/4885MEN1 1863/4885NPC1 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.